Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.

[1]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[2]  R. Jagsi,et al.  Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. , 2017, The Annals of thoracic surgery.

[3]  D. Harpole,et al.  Improved Survival of Stage I Non‐Small Cell Lung Cancer: A VA Central Cancer Registry Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  P. Aveyard,et al.  Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study , 2017, British Journal of Cancer.

[5]  C. Robinson,et al.  Treatment of stage I non–small cell lung cancer: What's trending? , 2017, The Journal of thoracic and cardiovascular surgery.

[6]  M. Janssen-Heijnen,et al.  Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients. , 2017, Lung cancer.

[7]  S. Dalton,et al.  Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison , 2017, Acta oncologica.

[8]  C. Gridelli,et al.  Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies , 2017, PloS one.

[9]  Å. Helland,et al.  Real-world data on nivolumab treatment of non-small cell lung cancer , 2017, Acta oncologica.

[10]  R. Bremnes,et al.  Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer , 2016, Acta oncologica.

[11]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[12]  B. Møller,et al.  Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage , 2016, International journal of cancer.

[13]  L. Kleinberg,et al.  EGFR mutation testing of lung cancer patients – Experiences from Vestfold Hospital Trust , 2016, Acta oncologica.

[14]  Jan Nyman,et al.  SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  B. Møller,et al.  Lung cancer survival in Norway, 1997–2011: from nihilism to optimism , 2015, European Respiratory Journal.

[16]  Reiner Leidl,et al.  Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. , 2015, Lung cancer.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  U. Pastorino,et al.  Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. , 2015, European journal of cancer.

[19]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[20]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[21]  B. Møller,et al.  Years of life lost as a measure of cancer burden on a national level , 2014, British Journal of Cancer.

[22]  Karl Erik Lund,et al.  Rusmidler i Norge 2013 , 2014 .

[23]  Janez Stare,et al.  On Estimation in Relative Survival , 2012, Biometrics.

[24]  L. Kleinberg,et al.  [Mutation testing for non-small-cell lung cancer]. , 2012, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[25]  Å. Helland,et al.  Sex-specific trends in lung cancer incidence and survival: a population study of 40 118 cases , 2011, Thorax.

[26]  Jose Belderbos,et al.  Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Gray,et al.  Do changes in cigarette design influence the rise in adenocarcinoma of the lung? , 2010, Cancer Causes & Control.

[28]  Bjørn Møller,et al.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. , 2009, European journal of cancer.

[29]  N. Wilking,et al.  Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study , 2008, Thorax.

[30]  R. Bremnes,et al.  Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity , 2007, British Journal of Cancer.

[31]  R. Bremnes,et al.  Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer , 2006, British Journal of Cancer.

[32]  H. Brenner,et al.  Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. , 2004, European journal of cancer.

[33]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[34]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.